Bispecific CD20-directed CD3 T Cell Engager [EPC]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Bispecific CD20-directed CD3 T Cell Engager [EPC] includes 2 drugs with a combined 3,157 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
3,157
Combined Reports
All Bispecific CD20-directed CD3 T Cell Engager [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| EPCORITAMAB | EPKINLY | 2,041 | 430 | 1,652 | 21.1% |
| GLOFITAMAB | Columvi | 1,116 | 315 | 492 | 28.2% |
Common Side Effects in Bispecific CD20-directed CD3 T Cell Engager [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Cytokine release syndrome | 966 | 168 |
| Off label use | 358 | 106 |
| Pyrexia | 336 | 66 |
| Febrile neutropenia | 288 | 21 |
| Disease progression | 262 | 120 |
| Pneumonia | 195 | 49 |
| Neutropenia | 193 | 42 |
| Covid-19 | 187 | 36 |
| Death | 185 | 185 |
| Sepsis | 135 | 61 |